GAIT
This article was originally published in The Tan Sheet
Executive Summary
Glucosamine/Chondroitin Arthritis Intervention Trial has begun patient recruitment, NIH announces Dec. 11. The $14 mil. study, co-sponsored by NCCAM and the National Institute of Arthritis & Musculoskeletal & Skin Diseases, has expanded over last eight months to a 24-week, placebo-controlled, parallel, double-blind, five-arm clinical trial assessing efficacy of supplements in treating knee pain of osteoarthritis. An additional $3.4 mil. "sub-study" jointly funded by NCCAM and NIAMS has been added to primary trial to evaluate whether ingredients impact progression of knee OA. Half of patients enrolled in initial trial will receive blinded treatment for an additional 18 months, and knee radiographs obtained at onset of treatment and after one and two years will be compared and evaluated for any structural change